<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Clinical presentation, pathologic features, and diagnosis of Sézary syndrome</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Clinical presentation, pathologic features, and diagnosis of Sézary syndrome</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Clinical presentation, pathologic features, and diagnosis of Sézary syndrome</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Alain H Rook, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Elise A Olsen, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Timothy M Kuzel, MD, FACP</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">John A Zic, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Alan G Rosmarin, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jul 28, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H449460985"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Sézary syndrome (SS) and mycosis fungoides (MF) are the most common subtypes of cutaneous T cell lymphoma (CTCL) [<a href="#rid1">1</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Mycosis fungoides</strong> – MF is a mature T cell non-Hodgkin lymphoma that presents with localized or widespread skin lesions, including erythroderma, patches, plaques, or tumors; lymph nodes, blood, and viscera may also be involved. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Sézary syndrome</strong> – SS is a distinctive erythrodermic CTCL with leukemic involvement by malignant T cells that typically bear the same T cell receptor rearrangement as the clone in the skin; occasionally, skin and blood clones do not match, but this should not dissuade one from considering the diagnosis. SS may present de novo with typical skin, blood, and nodal involvement or it may evolve from patch/plaque or erythrodermic MF. </p><p></p><p>MF and SS share certain pathologic and clinical features, and the same histologic criteria are used to diagnose and stage SS and all stages and types of MF [<a href="#rid2">2</a>]. However, patients with SS are generally more symptomatic, have lower rates of remission, and have inferior survival compared with patients with MF.</p><p>This topic discusses the clinical presentation, pathologic features, diagnosis, and differential diagnosis of SS. </p><p>Treatment of SS is discussed separately. (See  <a class="medical medical_review" href="/d/html/16616.html" rel="external">"Treatment of Sézary syndrome"</a>.)</p><p>Diagnosis and management of MF are discussed separately.</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/1674.html" rel="external">"Clinical manifestations, pathologic features, and diagnosis of mycosis fungoides"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/4757.html" rel="external">"Treatment of early stage (IA to IIA) mycosis fungoides"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/4759.html" rel="external">"Treatment of advanced stage (IIB to IV) mycosis fungoides"</a>.)</p><p></p><p class="headingAnchor" id="H449461398"><span class="h1">PATHOPHYSIOLOGY</span><span class="headingEndMark"> — </span>The cause of most cases of SS remains unclear [<a href="#rid3">3</a>]. Numerous gene mutations and deletions have been associated with SS, but their roles as oncogenic drivers are uncertain. A small percentage of cases are associated with human T-lymphotropic viruses type 1 and 2 (HTLV-I/II). </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cellular origin</strong> – Tumor cells in SS appear to be derived from skin-homing CD4-positive (CD4+) T cells or central memory T cells. Expression of cutaneous lymphocyte antigen (CLA) and high levels of the chemokine receptors CCR4 and CCR7 provide the T cells with the capacity to traffic bi-directionally into and out of the skin in response to the appropriate chemokines [<a href="#rid4">4,5</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Immunosuppression</strong> – Increased production of type 2 T helper cell (Th2) cytokines has been implicated in some of the characteristic immune abnormalities associated with SS [<a href="#rid6">6</a>]. Among the associated immune deficits are:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Decreased T cell responses to antigens and mitogens</p><p class="bulletIndent2"><span class="glyph">•</span>Impaired cell-mediated cytotoxicity, including natural killer (NK) cell activity</p><p class="bulletIndent2"><span class="glyph">•</span>Increased levels of serum immunoglobulin E (IgE)</p><p class="bulletIndent2"><span class="glyph">•</span>Peripheral eosinophilia</p><p class="bulletIndent2"><span class="glyph">•</span>Impaired dendritic cell functions</p><p></p><p class="bulletIndent1">Impaired immunity in patients with SS has been attributed, at least partially, to the increased production of Th2 cytokines by the malignant clone; these cytokines antagonize Th1 immunity and lead to decreased production of interleukin (IL)-12 and interferon (IFN) gamma, which are critical for anti-tumor immunity [<a href="#rid7">7,8</a>]. Activated T cells of patients with SS may also produce increased IL-10 and transforming growth factor (TGF)-beta, which can further impair cell-mediated immunity. In some cases, the malignant T cells can behave like regulatory T cells by manifesting FOXP3, increased CTLA4 expression, and enhanced production of IL-10 or TGF-beta, leading to suppression of normal T cell function [<a href="#rid9">9,10</a>]. Increased production of IL-31 by the malignant T cells has been associated with worsening pruritus among patients with SS [<a href="#rid11">11</a>]. </p><p></p><p class="bulletIndent1">Abnormalities of immune checkpoint molecules also contribute to depressed Th1 immunity and impaired cell-mediated immunity. Increased expression of programmed death domain 1 (PD-1) and other immune checkpoint molecules inhibit cytotoxic T cell function; anti-PD-1 monoclonal antibodies have been used to treat SS and mycosis fungoides (MF) [<a href="#rid12">12</a>]. TIGIT (T cell immunoreceptor with immunoglobulin and ITIM domain) is another checkpoint molecule that can suppress cellular immune functions in this setting [<a href="#rid13">13</a>]; TIGIT may be highly expressed by the malignant T cells and on CD8 T cells in the setting of SS, and high levels of TIGIT expression are associated with poor prognosis. The malignant T cells fail to normally upregulate CD40 ligand expression during activation, which may lead to impaired activation and differentiation of dendritic cells (DCs), which constitutively express CD40. A decline in the number and function of DCs parallels an increase in the circulating burden of malignant T cells. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Apoptosis</strong> – Defects in apoptosis are thought to lead to accumulation of the malignant T cells in vivo. Defects of proapoptotic pathways have been identified, including decreased expression of Fas (CD95), which may be due to hypermethylation of the <em>FAS</em> promoter [<a href="#rid14">14,15</a>]; treatment with <a class="drug drug_general" data-topicid="9630" href="/d/drug information/9630.html" rel="external">methotrexate</a>, IFN alpha, or IFN gamma can upregulate CD95 expression, thereby rendering cells more susceptible to Fas ligand-mediated death. Other apoptotic defects include increased expression of the apoptosis inhibitor cFLIP and tumor cell loss of TRAIL-receptor 2, leading to resistance to TRAIL. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cytogenetic/molecular abnormalities</strong> – Molecular abnormalities among individuals with SS/MF are heterogeneous. However, the pathophysiology appears to involve an intricate network of aberrant signaling through the T cell receptor, NFkB, CCR4/MAPK, and JAK/STAT pathways; aberrant tumor microenvironment, altered cell migration; and abnormal DNA damage response and chromatin structure [<a href="#rid16">16</a>]. Cytogenetic studies have revealed translocations and deletions in SS (eg, 1p, 10q, 14q, 15q) in conjunction with clonal evolution and chromosomal instability [<a href="#rid17">17,18</a>].</p><p></p><p class="bulletIndent1">Upregulation of<em> GATA3</em> and decreased expression of<em> STAT4</em> transcription factors may account for the Th2 phenotype in many cases of SS [<a href="#rid10">10</a>]. <em>TP53</em> alterations appear to be the most common molecular abnormality in SS, but mutations and/or deletions in <em>ZEB1, RB1, PTEN, DNMT3A, </em>and<em> CDKN1B </em>and gain-of-function mutations in the JAK-STAT pathway are often found [<a href="#rid19">19-21</a>]. T-plastin, an actin-bundling protein that is not normally expressed in hematopoietic cells, is expressed by malignant T cells of SS; this feature can facilitate identification of the lymphoma cells [<a href="#rid22">22</a>]. Somatically acquired single-nucleotide variants observed in cases of MF/SS most frequently involve C &gt; T transitions [<a href="#rid19">19,23-25</a>]; this mutational signature at CpG sites, which is uncommon in other hematological cancers, is associated with exposure to ultraviolet (UV) light.</p><p></p><p class="bulletIndent1">Gene expression profiles, microRNA profiling, and cell marker studies suggest that MF and SS may be distinct entities with differing pathogenesis [<a href="#rid5">5,26-28</a>]. Comparative genomic hybridization has identified chromosomal abnormalities that occur in both MF and SS and abnormalities that are present in either MF or SS, but not both [<a href="#rid29">29-32</a>]. Malignant T cells of SS express CD27, CCR7, L-selectin, and CCR4, which are markers of central memory T cells; by contrast, the malignant T cells of MF fail to express CCR7, L-selectin, and CD27, but do express high levels of CCR4 and CLA, which is typical of skin-resident effector T cells [<a href="#rid5">5</a>]. Hypotheses regarding the pathogenesis of MF are discussed separately. (See  <a class="medical medical_review" href="/d/html/1674.html" rel="external">"Clinical manifestations, pathologic features, and diagnosis of mycosis fungoides", section on 'Pathogenesis'</a>.)</p><p></p><p class="bulletIndent1">A small percentage of cases is associated with human T-lymphotropic viruses type 1 and 2 (HTLV-I/II) [<a href="#rid33">33-35</a>], which are endemic in southern Japan, Caribbean islands, the Middle East, and other locations. (See  <a class="medical medical_review" href="/d/html/4697.html" rel="external">"Clinical manifestations, pathologic features, and diagnosis of adult T cell leukemia-lymphoma"</a>.)</p><p></p><p class="headingAnchor" id="H449461419"><span class="h1">EPIDEMIOLOGY</span><span class="headingEndMark"> — </span>The incidence of SS is not well-defined. SS is an acquired disorder; it is not reported in family clusters. </p><p>In the United States, analysis of the Surveillance, Epidemiology and End Results (SEER) data from 2001 to 2005 estimated the incidence of cutaneous T cell lymphomas at 0.8 cases per million persons per year, with a male:female ratio of 2.11 [<a href="#rid36">36</a>]. Similarly, the Cancer Registry of Norway from 2000 to 2003 estimated the incidence at approximately 0.9 cases per million persons per year [<a href="#rid37">37</a>]. </p><p>SS is a disease of older adults with very few cases reported among patients &lt;30 years old [<a href="#rid38">38</a>]. In the United States, the incidence appears higher among White Americans (0.36 cases per million persons per year) than among Black Americans (0.04 cases per million persons per year). However, a retrospective single-center study of 393 patients with SS from Georgia (a state in which nearly one-third of residents self-identify as African American) reported that 55 percent of patients were White American and 43 percent were African American [<a href="#rid39">39</a>]. </p><p>SS is not inherited, and siblings and children of patients with SS do not have an increased risk of developing SS. A relationship of chemical exposure with mycosis fungoides (MF)/SS has been reported [<a href="#rid40">40</a>], and a study of MF/SS in Canada reported geographic clustering of cases in industrial areas [<a href="#rid41">41</a>].</p><p class="headingAnchor" id="H449461426"><span class="h1">CLINICAL MANIFESTATIONS</span><span class="headingEndMark"> — </span>Patients with SS generally present with diffuse skin involvement, rather than evolving through patches and plaques to erythroderma. Adenopathy and pruritus are common and can profoundly affect quality of life [<a href="#rid42">42</a>]. Patients who evolve from typical mycosis fungoides (MF) lesions to erythroderma and a leukemic phase of blood involvement (eMF), may show the same manifestations as SS.  </p><p class="headingAnchor" id="H1059750"><span class="h2">Skin</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cutaneous lesions</strong> – Patients with SS commonly present with widespread erythema  (<a class="graphic graphic_picture graphicRef83372" href="/d/graphic/83372.html" rel="external">picture 1</a>), which can be finely scaly, indurated, or even resemble livedo reticularis. The severity of erythema and the body surface area (BSA) involved may wax and wane, but at some point in the disease course, the skin involvement should cover &gt;80 percent BSA to meet the definition of erythroderma from the International Society for Cutaneous Lymphoma (ISCL), United States Cutaneous Lymphoma Consortium (USCLC), and European Organization of Research and Treatment of Cancer (EORTC) [<a href="#rid43">43</a>]. (See  <a class="medical medical_review" href="/d/html/1674.html" rel="external">"Clinical manifestations, pathologic features, and diagnosis of mycosis fungoides", section on 'Skin lesions'</a>.)</p><p></p><p class="bulletIndent1"> Other skin lesions that may be present with SS include:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Keratosis pilaris-like lesions</strong> – Inflamed follicular-based papules or scale may signal follicular involvement  (<a class="graphic graphic_picture graphicRef83372" href="/d/graphic/83372.html" rel="external">picture 1</a>). </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Alopecia</strong> – Alopecia is common and can present as reduced hair density diffusely over the scalp and body or as patches of alopecia  (<a class="graphic graphic_picture graphicRef83374 graphicRef83373" href="/d/graphic/83374.html" rel="external">picture 2A-B</a>).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Ectropion</strong> – An outward turning of the lower eyelid with increased exposure of the ocular surface and sensitive mucous membranes of the inner lid can develop because of the tautness and induration in the skin and may be associated with disruption of normal tear drainage patterns. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Keratoderma</strong> – Thickened retention of keratin on the palms and soles (keratoderma) is a common finding and can help to distinguish SS from other causes of erythroderma, but it can occasionally make the distinction between SS and pityriasis rubra pilaris difficult  (<a class="graphic graphic_picture graphicRef83371" href="/d/graphic/83371.html" rel="external">picture 3</a>). </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Hypertrophic nails</strong> – Nails may become hypertrophic due to posterior nail fold involvement.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Leonine facies</strong> – Infiltration (thickening) of the facial skin leading to prominent convexities and furrowed creases.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Erosions and superinfection</strong> – Patients are often colonized with <em>Staphylococcus aureus</em>, and erosions and superinfection from constant scratching are common.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Focal areas of scaling</strong> – Tinea corporis is common; a potassium hydroxide preparation performed where scaly patches predominate can aid in diagnosis. (See  <a class="medical medical_review" href="/d/html/13690.html" rel="external">"Approach to the patient with annular skin lesions", section on 'Diagnostic tests'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Lichenification</strong> – Diffuse lichenification, characterized as thickened skin with increased skin lines, may occur with long-standing disease, chronic pruritus, and scratching. Fissures are common.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pruritus</strong> – Pruritus is the most common and debilitating symptom of patients with SS [<a href="#rid44">44</a>]. Pruritus may exacerbate sleep dysfunction, anxiety, and depression. The degree of pruritus is not necessarily related to the degree of blood involvement or the extent and depth of erythema. Pruritus may be triggered by a variety of mediators related to the tumor microenvironment including interleukins (IL) characteristic of the Th2 cytokine profile or IL-31 [<a href="#rid11">11,45</a>]. Therapy that ameliorates the extent and severity of both skin and blood involvement improves pruritus.</p><p></p><p class="bulletIndent1">Management of pruritus in MF or SS with skin-directed and systemic antipruritic agents is described separately. (See  <a class="medical medical_review" href="/d/html/4757.html" rel="external">"Treatment of early stage (IA to IIA) mycosis fungoides"</a>.)</p><p></p><p class="headingAnchor" id="H3360838949"><span class="h2">Extracutaneous</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Lymphadenopathy</strong> – Peripheral lymphadenopathy is common in SS, but it may go undetected by physical examination, especially in patients with obesity. Imaging is required to determine enlargement of both peripheral and central nodes. Lymph nodes &gt;1.5 cm in long diameter (LDi) are considered abnormal [<a href="#rid46">46</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Viscera </strong>– The incidence of visceral involvement in patients with MF and SS is poorly defined. </p><p></p><p class="bulletIndent1">At present, solid organ involvement in SS is defined by imaging and is only infrequently reported. However, early studies that performed liver and bone marrow biopsies at initial staging found a high incidence (6/18) of visceral involvement in patients with erythroderma; blood involvement was not specified [<a href="#rid47">47</a>]. </p><p></p><p class="bulletIndent1">The incidence of bone marrow involvement is largely unknown, since bone marrow biopsies are not routinely performed unless there are unexplained abnormal hematologic parameters. </p><p></p><p class="headingAnchor" id="H1059838"><span class="h2">Associated conditions</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Infections</strong> – Patients with SS are at increased risk for infection due to an underlying immune dysfunction and physical factors. </p><p></p><p class="bulletIndent1">Patients with SS have impaired cellular and humoral immunity and increased severity of viral (eg, herpes), dermatophyte, and bacterial infections, especially <em>S. aureus </em>[<a href="#rid48">48</a>]. In one study, most patients with SS had colonization of skin or nares with <em>S. aureus</em> [<a href="#rid49">49</a>]. With concomitant pruritus, there are frequent excoriations and potential for bacteremia.</p><p></p><p class="bulletIndent1">It is important to remember that body temperature can be normal in the face of bacteremia, due to the loss of body heat through dilated skin vasculature and a disrupted skin barrier. There should be a low threshold to check blood cultures in patients with new constitutional symptoms, particularly if they have either a high white blood cell count or low neutrophil count or if the patient has a port, indwelling line, or is undergoing photopheresis and to consider use of antibiotics while awaiting blood culture results. Patients treated with antibiotics to cover staphylococci may also show improvement in their skin lesions. </p><p></p><p class="bulletIndent1">Patients taking <a class="drug drug_general" data-topicid="8725" href="/d/drug information/8725.html" rel="external">alemtuzumab</a>, a particularly effective treatment for SS, are prone to bacterial, fungal, and viral skin infections, especially cytomegalovirus (CMV) [<a href="#rid50">50</a>]. There have also been reports of progressive multifocal leukoencephalopathy (PML) due to polyomavirus in patients with SS in the absence of immunosuppressive therapy [<a href="#rid51">51</a>] and at least one therapy for MF/SS (brentuximab) has been associated with PML [<a href="#rid52">52</a>].</p><p></p><p class="bulletIndent1">Management of infections in patients with SS is discussed separately. (See  <a class="medical medical_review" href="/d/html/16616.html" rel="external">"Treatment of Sézary syndrome", section on 'Prevention of infections'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Second malignancies</strong> – There is an increased incidence of second cancers (especially other lymphomas) in patients with MF or SS [<a href="#rid53">53-55</a>]. Whether this is related to an inherent impairment of immune surveillance or prior treatments is not clear. There is also an increased incidence of melanoma and squamous cell carcinoma. </p><p></p><p class="bulletIndent1">As an example, an analysis of the US Surveillance, Epidemiology, and End Results Program (SEER) registry reported 197 second malignancies among 1798 patients with an initial diagnosis of MF or SS [<a href="#rid53">53</a>]. When compared with age-, sex-, and race-matched persons from the general population, patients with MF or SS had a significantly higher rate of the following (as expressed using the standardized incidence ratio [SIR]):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Hodgkin lymphoma (SIR 17.1 [95% CI 6.3-37.3])</p><p class="bulletIndent2"><span class="glyph">•</span>Non-Hodgkin lymphoma (SIR 5.1 [95% CI 3.3-7.4])</p><p class="bulletIndent2"><span class="glyph">•</span>Melanoma (SIR 2.6 [95% CI 1.3-4.8])</p><p class="bulletIndent2"><span class="glyph">•</span>Urinary cancer (SIR 1.7 [95% CI 1.1-2.7]) </p><p></p><p class="headingAnchor" id="H605166678"><span class="h1">EVALUATION</span><span class="headingEndMark"> — </span>SS should be considered in any patient presenting with erythroderma, regardless of underlying or preceding skin conditions that can cause erythroderma. It should also be considered in any patient with a persistent erythematous skin rash unresponsive to topical steroids and accompanied by pronounced pruritus.</p><p class="headingAnchor" id="H674535346"><span class="h2">Routine blood work</span><span class="headingEndMark"> — </span>Complete blood count (CBC) with differential, complete metabolic panel, liver function tests, lactate dehydrogenase (LDH). All patients with mycosis fungoides (MF) or SS should be tested for human T-lymphotrophic virus (HTLV)-I/II to evaluate for adult T cell leukemia-lymphoma (ATLL) [<a href="#rid43">43</a>]; this is especially important in patients with CD8+ or CD25+ infiltrates or from endemic areas [<a href="#rid4">4,56</a>]. </p><p>In circumstances where immunosuppressive therapy is indicated, testing for human immuno deficiency virus (HIV), hepatitis B and C, and tuberculosis should be performed. </p><p class="headingAnchor" id="H3457435339"><span class="h2">Skin biopsy</span><span class="headingEndMark"> — </span>The initial evaluation should include a biopsy of involved skin with assessment of the morphology, immunophenotype, and <em>TCR</em> (T cell receptor gene) clonality of cellular infiltrates. </p><p>It is always best to biopsy the most indurated area of skin. If more than one type of lesion (eg, confluent patchy erythema, follicular-based papules, alopecia, or livedo-like erythema) is present, a biopsy of each representative type of lesion should be performed. This helps to determine both the extent of involvement and identifies certain prognostic factors, such as folliculotropism. A punch biopsy should be ≥4 mm. Clonality studies can be performed on formalin-fixed tissue, but the yield is greater when the tissue is collected on <a class="drug drug_general" data-topicid="9929" href="/d/drug information/9929.html" rel="external">saline</a> and immediately submitted for preparation/assessment.</p><p>Because the skin infiltrate in SS is generally much less dense than that of plaque stage MF, it is important to minimize interventions that could affect the infiltrate prior to taking the biopsy, including topical or systemic corticosteroids and any other immunosuppressive medication. In general, these agents, especially topical steroids, should be discontinued for at least 14 days prior to skin biopsy to help maximize the potential for a firm diagnosis.</p><p class="headingAnchor" id="H4266241506"><span class="h2">Lymph node assessment</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Imaging</strong> – Positron emission tomography/computed tomography (PET/CT) or CT of neck, chest, abdomen, and pelvis is recommended to determine whether there are any abnormal peripheral or central nodes. </p><p></p><p class="bulletIndent1">Both imaging methods allow tracking the size and number of lymph nodes judged to be of concern (ie, long diameter [LDi] &gt;1.5 cm) [<a href="#rid43">43</a>], but PET/CT offers additional information through metabolic scoring. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Biopsy of representative lymph node</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Choice of lymph node for biopsy</strong> –<strong> </strong>The choice of lymph node for biopsy is of great importance as the pathologic assessment will be applied to all abnormal lymph nodes. The preferred lymph node for biopsy is the largest accessible peripheral node draining an area of involved skin, the one with the most concerning morphological features on imaging, and if PET data are available, the one that shows the highest standardized uptake value (SUV) [<a href="#rid43">43</a>]. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Choice of type of lymph node biopsy </strong>–<strong> </strong>An excisional biopsy is preferred since lymph node staging in MF and SS is dependent on pathologic architectural changes. A core biopsy may suffice if sufficient tissue is available for all standard and ancillary assessments [<a href="#rid43">43</a>]. Biopsy permits not only staging but evaluation for other causes of node enlargement. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Methods of assessment of lymph node </strong>–<strong> </strong>Evaluation by light microscopy and immunophenotyping, the latter by either immunohistochemistry or by flow cytometry, is necessary. <em>TCR</em> gene rearrangement clonality is not required but, if performed, is expected to match that of skin. </p><p></p><p class="headingAnchor" id="H1665359895"><span class="h2">Viscera assessment</span><span class="headingEndMark"> — </span>As with lymph node assessment, imaging is key to determining visceral involvement and should be based on Lugano criteria [<a href="#rid46">46</a>]. </p><p>Either PET/CT or contrast-enhanced CT of neck, chest, abdomen, and pelvis should be performed. Biopsy of potential visceral involvement would be indicated if using CT scan for assessment, but if using PET/CT, one could use metabolic assessment per Lugano guidelines.  </p><p>Bone marrow (BM) examination is currently only required for unexplained hematologic abnormalities. If performed to assess SS, involvement should be based on core biopsy, not by imaging [<a href="#rid43">43</a>].</p><p class="headingAnchor" id="H976650039"><span class="h2">Blood assessment</span><span class="headingEndMark"> — </span>There are many ways to assess blood involvement by lymphoma in SS. The methods depend on what is available at the institution/practice and the most recent advances in this area. There is no current algorithm for using all methods collectively.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cytological evaluation/Sezary cells </strong>– The peripheral blood of patients with SS is characterized by a large number of atypical mononuclear cells with moderately to highly grooved (ie, cerebriform) nuclei and a high nuclear to cytoplasmic ratio, termed Sézary cells  (<a class="graphic graphic_picture graphicRef75793" href="/d/graphic/75793.html" rel="external">picture 4</a> and <a class="graphic graphic_picture graphicRef70592" href="/d/graphic/70592.html" rel="external">picture 5</a>). Sézary cells are best demonstrated on a buffy coat preparation of the peripheral blood, also called a "Sézary cell" prep. Typical Sézary cells are larger than a normal resting lymphocyte, and approximate the size of a normal monocyte [<a href="#rid57">57</a>]. However, a subset of patients demonstrates a smaller variant of Sézary cells that are approximately the size of a resting lymphocyte. </p><p></p><p class="bulletIndent1">The cerebriform nuclear morphology that characterizes Sézary cells is not specific for neoplastic T cells [<a href="#rid57">57</a>]. Small numbers of Sézary-like cells can be observed in the peripheral blood of healthy individuals or those with other benign or malignant diseases [<a href="#rid2">2</a>].</p><p></p><p class="bulletIndent1">Sézary cell counts are subjective and there is considerable inter-observer variability. However, they may be useful in clinical practice to help track blood involvement in patients who are CD8+ or negative for both CD4 and CD8 in the skin or blood. Reliability is increased if the assessment is performed by the same cytopathologist(s) each time. Sézary cell counts are usually reported as a percentage of lymphocytes examined; the absolute count is determined by multiplying the percentage by the absolute lymphocyte count of the CBC.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Flow cytometry</strong> – Flow cytometry is objective, quantifiable, and reproducible and the preferred method for the determination of blood involvement, staging, monitoring of patients on therapy, and determining response in clinical trials of MF and SS [<a href="#rid43">43,58,59</a>]. </p><p></p><p class="bulletIndent1">Although there are no current specific guidelines, a single effective, validated and universally accepted method and biomarker set to identify and track the blood tumor burden by flow cytometry is needed for MF and SS. One group of international experts in hematopathology has recommended a set of gating principles to standardize the methodology of flow cytometry and a set of at least 6 standard markers [<a href="#rid60">60</a>]. The EuroFlow consortium has developed a sensitive and standardized multiparameter flow cytometry with a gating strategy based on whole phenotypic parameters [<a href="#rid61">61</a>]. Many new markers have been suggested but in the absence of a standardized and uniformly accepted approach, the determination of blood tumor involvement by absolute counts of CD4+, CD26- and/or CD4+, CD7- subsets remains [<a href="#rid43">43</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong><em>TCR</em></strong><strong> gene rearrangement clonality </strong>–<em> TCR</em> gene rearrangement to assess clonality of circulating lymphocytes is important to confirm the relationship of abnormal cells in peripheral blood to the skin lymphoma. The <em>TCR</em> clone should generally match that in the skin, recognizing that more than one clonal rearrangement may be found. Due to plasticity of the neoplastic cells over time or with treatment, different clones may be selected as the major component in blood, or a new clone may emerge over the course of the patient’s illness. An international study observed that clonality-discordance between skin and blood appeared to be associated with improved survival [<a href="#rid62">62</a>].</p><p></p><p class="headingAnchor" id="H159357528"><span class="h1">PATHOLOGY</span></p><p class="headingAnchor" id="H4275185099"><span class="h2">Skin pathology</span><span class="headingEndMark"> — </span>A diagnostic skin biopsy may be difficult to make in patients with SS, potentially requiring multiple biopsies and even the added input of blood flow cytometry and lymph node biopsy to confirm the diagnosis of SS. </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Light microscopic findings</strong> – A biopsy of representative erythrodermic skin with routine hematoxylin and eosin staining technique is rarely sufficient to diagnose mycosis fungoides (MF). </p><p></p><p class="bulletIndent1">Generally, there are atypical lymphocytes in a sparse dermal infiltrate along with epidermotropism (movement of the atypical lymphocytes into the epidermis), which is suggestive, but not diagnostic, of MF; epidermotropism may be completely absent in biopsies from SS patients. The more diagnostic intra-epidermal aggregates of atypical cells (ie, Pautrier microabscesses) may or may not be present. Significant edema and a nonspecific infiltrate of inflammatory T cells may predominate, making diagnosis more difficult [<a href="#rid57">57</a>]. </p><p></p><p class="bulletIndent1">Histologic findings in affected skin in SS and MF are described in more detail separately. (See  <a class="medical medical_review" href="/d/html/1674.html" rel="external">"Clinical manifestations, pathologic features, and diagnosis of mycosis fungoides", section on 'Skin biopsy'</a>.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Immunophenotyping</strong> – The immunophenotype of the tumor cells (typically CD3+, CD4+) is usually established by immunohistochemistry using formalin-fixed tissue. The panel of markers typically includes at least CD3, CD5, CD4, CD8, CD7, CD30, and a B cell marker (eg, CD20), but it would be expanded depending on the differential suggested by the light microscopic findings. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clonality </strong>– Clonality of <em>TCR</em> (T cell receptor gene) is consistent with, but not diagnostic of MF and SS, because T cell clones may be present in skin in many nonmalignant skin disorders [<a href="#rid63">63-65</a>]. </p><p></p><p class="bulletIndent1">Polymerase chain reaction (PCR) is sensitive for detecting clonality in MF/SS, but its utility depends on the specific technique (Biomed-2 primer sets/protocols are the preferred methods [<a href="#rid43">43</a>]) and the presence of enough tumor cells in the tissue submitted for testing. Thus, the size and type of skin lesion(s) selected for biopsy is key. Initial clonality testing typically addresses potential<em> TCR </em>gamma/delta rearrangements. However, if these studies are negative, they should be followed by testing for<em> TCR</em> alpha/beta rearrangement. </p><p></p><p class="bulletIndent1">Next-generation sequencing (NGS)/high-throughput sequencing (HTS) of<em> TCR</em> beta and gamma third complementarity determining regions is more sensitive than PCR for detecting clones within skin and blood and can better discriminate between MF/SS and a benign inflammatory process [<a href="#rid66">66</a>].</p><p></p><p class="bulletIndent1">If a clonality study is negative or indeterminate using formalin-fixed tissue, another skin biopsy collected on <a class="drug drug_general" data-topicid="9929" href="/d/drug information/9929.html" rel="external">saline</a> may have greater yield. It is not unusual to identify more than one clone in tissue and/or blood, which may reflect the plasticity of the aberrant lymphocytes and/or clonal evolution in an individual.</p><p></p><p>In situations where the diagnosis by skin biopsy is still equivocal, the diagnosis of SS may be made by blood studies or nodal biopsy, described below. (See <a class="local">'Additional methods to establish diagnosis of SS'</a> below.)</p><p class="headingAnchor" id="H4095807699"><span class="h2">Lymph node pathology</span><span class="headingEndMark"> — </span>In contrast to other types of primary cutaneous lymphoma, enlarged lymph nodes in MF and SS may demonstrate reactive changes, dermatopathic features, or frank lymphoma. </p><p>The amount and/or size of the abnormal lymphocytes and the degree of effacement of the normal lymph node architecture are used to give a grade of involvement, using either of the two different scoring systems (NCI and Dutch) [<a href="#rid2">2</a>]. An NCI grade LN4 and a Dutch grade 3/4 are both indicative of nodal lymphoma (N3 involvement). <em>TCR</em> clonality testing would be expected to find a positive clone that matches that in skin lesions. Further details of grading are discussed separately. (See  <a class="medical medical_review" href="/d/html/83281.html" rel="external">"Staging and prognosis of mycosis fungoides and Sézary syndrome"</a>.)</p><p>The importance of the choice of node for biopsy cannot be overstated. In one report of 22 patients with SS and a node &gt;1.5 cm in diameter by CT, all 12 node biopsies that met criteria for N3 were of the largest node (or equivalent in size to the largest node); the majority of biopsies of smaller nodes had N1 or N2 characterization [<a href="#rid67">67</a>]. The importance of biopsying abnormal nodes is illustrated by the finding that 3 of 22<strong> </strong>patients with SS had findings of tuberculosis, adenocarcinoma, or diffuse large B cell lymphoma.</p><p class="headingAnchor" id="H2850668626"><span class="h2">Viscera pathology</span><span class="headingEndMark"> — </span>Patients with imaging abnormalities suggestive of MF/SS should have pathologic documentation, or they should be judged as Mx. If abnormalities were discovered on PET/CT, metabolic scoring can be used to suggest involvement and a means of tracking treatment response, as per Lugano guidelines [<a href="#rid46">46</a>]. </p><p>Patients with SS in whom a bone marrow (BM) core biopsy shows nodular, diffuse, or interstitial involvement (&gt;5 percent of BM cellularity) and where the immunophenotype and molecular findings are consistent with those of the skin biopsy are considered to have marrow involvement and are classified as M1A [<a href="#rid43">43</a>].</p><p class="headingAnchor" id="H3133045159"><span class="h1">DIAGNOSIS</span><span class="headingEndMark"> — </span>The diagnosis of SS is based upon the extent and type of skin involvement (erythroderma), a pathologic evaluation of the skin, and peripheral blood findings, interpreted within the clinical context.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Skin</strong> – The skin biopsy may be only suggestive of MF/SS on light microscopic examination, but the pertinent immunophenotyping studies and a positive <em>TCR</em> rearrangement demonstrating clonality can be used to confirm the diagnosis. (See <a class="local">'Skin pathology'</a> above.)</p><p></p><p class="bulletIndent1">In situations where the diagnosis by skin biopsy is still equivocal, the diagnosis may be made by blood studies or nodal biopsy. Immunophenotype, molecular biomarkers, mutations in DNA epigenetic enzymes, and cytogenetics may be useful for differentiating SS from other erythrodermic conditions. </p><p></p><p class="bulletIndent1">For patients in whom the skin biopsy is not diagnostic for mycosis fungoides (MF)/SS, alternative diagnostic methods are described below. (See <a class="local">'Additional methods to establish diagnosis of SS'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Blood</strong> – A diagnosis of SS requires a significant level of blood involvement that should reach the B2 staging characterization and a positive <em>TCR</em> clone in the blood that matches the skin. (See <a class="local">'Staging'</a> below.)</p><p></p><p class="bulletIndent1">There are several methods to quantitate blood involvement: </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The ISCL/USCLC/EORTC consortium currently recommends using absolute counts of CD4+CD7- and CD4+CD26 lymphocytes to determine B staging and for tracking purposes in MF/SS [<a href="#rid43">43</a>]. The absolute number may be calculated from the percentage of the aberrant lymphocytes (from flow cytometry) x the absolute lymphocyte count (from the complete blood count [CBC]). </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Sézary cell counts may also be used, with the calculation based on percentage of Sézary cells x absolute lymphocyte count (from the CBC). </p><p></p><p class="headingAnchor" id="H1485426069"><span class="h2">Diagnostic criteria</span><span class="headingEndMark"> — </span>Consensus criteria for the classification as SS requires each of the following three criteria [<a href="#rid2">2,43</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Skin</strong> – One of the following:</p><p></p><p class="bulletIndent1">Biopsy is diagnostic of MF/SS </p><p></p><p class="bulletIndent1">or</p><p></p><p class="bulletIndent1">Skin biopsy is compatible/suggestive of MF/SS <strong>plus</strong>:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Biopsy of enlarged lymph node confirming MF/SS </p><p></p><p class="bulletIndent2">or</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Significant aberrant lymphocyte population in blood with positive <em>TCR</em> clone matching that in skin</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Erythroderma</strong> – Erythema covering ≥80 percent of body surface area.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Leukemic blood tumor burden</strong> – Both of the following:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>B2 blood involvement</strong> – To characterize blood involvement in SS, it is important to define the levels of aberrant lymphocytes integral to B staging [<a href="#rid43">43</a>]. B0 is currently defined as &lt;250/microL Sézary cell count, or CD4+CD26- or CD4+CD7- lymphocytes. B2 blood involvement, typically seen with untreated SS, is currently defined as &gt;1000/microL of Sézary cells or CD4+CD26- or CD4+CD7- lymphocytes. B1 is defined as not meeting the criteria for B0 or B2.</p><p></p><p class="bulletIndent2">For patients with lymphopenia (&lt;1000 lymphocytes/microL), it is difficult to use absolute counts of aberrant lymphocyte subsets to establish B2 without underestimating the severity of the blood tumor burden. In the face of lymphopenia, the percentage of the aberrant lymphocyte subsets may have greater relevance [<a href="#rid43">43</a>]. The ISCL previously reported on B2 assignment based on 40 percent CD4+CD7- and 30 percent of CD4+CD26- cells [<a href="#rid59">59</a>], but the specificity of the latter percentages for lymphoma has come into question. In one report, &gt;40 percent CD4+CD7- cells were found in 54 percent of patients with SS but in none with erythrodermic inflammatory dermatoses (EID; sensitivity 54 percent, specificity 100 percent), and &gt;30 percent CD4+CD26- cells were found in 86 percent of patients with SS but in 53 percent of patients with EID (sensitivity 86 percent, specificity 47 percent). If the CD4+CD26- threshold was raised to &gt;80 percent, then this was seen in 66 percent of SS patients and none of the EID patients [<a href="#rid60">60</a>]. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong><em>TCR</em></strong><strong> clonality</strong> – A clonal <em>TCR</em> rearrangement in blood that matches that in skin. Abnormal <em>TCR</em> clones in blood that do not match skin can be considered unrelated to the process in the skin and may be related to age.</p><p></p><p class="bulletIndent1">Designation as T4 (erythroderma) plus B2 designation in the tumor-node-metastasis-blood (TNMB) classification system fulfills the criteria for SS. There may also be cases where a large population of abnormal lymphocytes in the blood are not represented by these specific CD4+CD7- and CD4+CD26- subsets and that could also represent B2 involvement of SS.  </p><p></p><p class="bulletIndent1">If the work-up is inconclusive, but the diagnosis of SS is still suspected, the patient should continue to be re-evaluated over time, as those originally presenting with MF may evolve to SS. In one study with a median follow-up of 1.6 years (range, 0.5 to 9 years), 6 of 31 erythrodermic MF patients (eMF) with B1 blood staging evolved toward SS in a median of 1.2 years (range, 0.5 to 2.5 years), all of them expressing blood biomarkers [<a href="#rid68">68</a>].</p><p></p><p class="headingAnchor" id="H2600828607"><span class="h2">Additional methods to establish diagnosis of SS</span><span class="headingEndMark"> — </span>Biopsies of patch lesions, like erythroderma, may not meet the pathologic diagnostic criteria for MF based on microscopy, immunophenotyping, and molecular studies. When the skin biopsy does not provide a firm diagnosis, alternative methods may be used to aid the diagnosis of SS/MF; alternate methods include a diagnostic algorithm, evaluation of other involved tissues, and/or adjunctive studies to differentiate SS from other erythrodermic conditions, as follows. </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pathologic algorithm</strong> – An algorithm developed for the diagnosis of early MF may also be useful in SS [<a href="#rid69">69</a>]. Key pathological findings of this algorithm include the following criteria; four points are needed for a diagnosis of MF/SS:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Clinical</strong> – Persistent and/or progressive patches/thin plaques with one of the following (1 point) or two of the following (2 points):</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Variation in size/shape of lesions</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Non-sun exposed areas</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Poikiloderma</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Histopathological</strong> – Superficial lymphoid infiltrate with 1 point for one criterion and 2 points for both criteria: </p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Epidermotropism without spongiosis</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Lymphoid atypia </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Molecular/biological</strong> – Clonal <em>TCR</em> gene rearrangement (1 point).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Immunopathologic</strong> – Loss of mature T cell antigens (&lt;10 percent CD7+ T cells or &lt;50 percent CD2+CD3+ and/or CD5+ T cells) or epidermal/dermal discordance of CD2, CD3, CD5, or CD7 (1 point maximum).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Analysis of other involved tissues</strong> – If the findings on skin biopsy are only suggestive or inadequate for the diagnosis of MF or SS, evaluation of the peripheral blood with flow cytometry and clonality studies (with or without Sézary cell prep) can help to confirm the diagnosis. If imaging demonstrates nodal enlargement, diagnosis may also be forthcoming by biopsy of a representative abnormal lymph node.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Additional studies to differentiate erythrodermic inflammatory dermatoses from SS</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Studies have reported that the level of KIR3DL2, which is not present on normal CD4+ cells, represents the most sensitive diagnostic criterion of SS when compared with all other available biological criteria, and that an eosinophil cell count &gt;700/microL and &gt;85 percent CD3+KIR3DL2+ T cells at diagnosis were associated with a significantly reduced disease-specific survival [<a href="#rid68">68</a>]. KIR3DL2 immunostaining allowed the assessment of treatment efficiency and specificity toward tumor cells, detection of residual disease following treatment, and occurrence of relapse. High throughput sequencing may also be utilized to assess minimal residual disease.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Altered expression of <em>STAT4, TWIST1</em>, and either <em>DNM3</em> or <em>PLS3</em> was reported to distinguish 98 percent of patients with SS from patients with EID with 100 percent specificity [<a href="#rid17">17</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Another study reported a progressive increase in the expression of the biomarkers KIR3DL2, TWIST, PLS3 (T-plastin), and NKp46 from B0 to B1 through B2, suggesting a spectrum of eMF up to SS [<a href="#rid68">68</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><em>TP53</em> alterations appear to be the most common genetic mutation in SS [<a href="#rid21">21</a>]. Cytogenetic studies have revealed translocations and deletions in SS, especially 1p, 10q, 14q, and 15q, in conjunction with clonal evolution and chromosomal instability [<a href="#rid17">17,18</a>].</p><p></p><p class="headingAnchor" id="H2983563191"><span class="h1">STAGING</span><span class="headingEndMark"> — </span>Staging of MF/SS includes the nature, size, and amount of skin lesions; the extent and type of nodal and visceral involvement; and the blood tumor burden [<a href="#rid43">43</a>]. </p><p>Although all patients with SS will likely have erythroderma (T4) at some point, the T stage may change to T2 as the skin involvement waxes and wanes; this would not change the designation of SS. Enlarged lymph nodes without a biopsy documentation of lymphomatous involvement should be classified as Nx. Abnormalities of viscera in which neither imaging nor biopsy have established involvement with lymphoma should be defined as Mx for staging purposes. A separate classification of visceral disease in SS and MF has been developed specifically with SS in mind with M1A indicating BM involvement alone and M1B indicating other visceral organs involved. </p><p>Determination of blood involvement is described above. (See <a class="local">'Diagnostic criteria'</a> above.)</p><p>Details of staging are discussed separately. (See  <a class="medical medical_review" href="/d/html/83281.html" rel="external">"Staging and prognosis of mycosis fungoides and Sézary syndrome"</a>.)</p><p class="headingAnchor" id="H449462806"><span class="h1">DIFFERENTIAL DIAGNOSIS</span><span class="headingEndMark"> — </span>SS typically presents with generalized erythroderma and blood involvement by the malignant T cells (Sézary cells). Other cutaneous findings may be present that help to distinguish SS from benign inflammatory dermatoses and secondary lymphomas. (See <a class="local">'Additional methods to establish diagnosis of SS'</a> above.)</p><p>The differential diagnosis includes erythrodermic mycosis fungoides (eMF), other primary cutaneous disorders that present with erythroderma, drug eruptions, and other lymphoproliferative or hematologic malignancies that have circulating malignant T cells.</p><p class="headingAnchor" id="H63648246"><span class="h2">Mycosis fungoides</span><span class="headingEndMark"> — </span>Mycosis fungoides (MF) and SS share many pathophysiologic and clinical features and therapeutic approaches.</p><p>Patients with eMF have varying degrees of blood involvement.<strong> </strong>The diagnosis of SS specifically requires that patients either meet the criteria of MF/SS in the skin or that the skin biopsy is suggestive of MF/SS and other parameters (ie, blood or nodal involvement) cement the diagnosis. (See <a class="local">'Diagnostic criteria'</a> above.)</p><p>For SS, patients should also meet the criteria of B2 involvement. (See  <a class="medical medical_review" href="/d/html/1674.html" rel="external">"Clinical manifestations, pathologic features, and diagnosis of mycosis fungoides"</a>.)</p><p class="headingAnchor" id="H1060516"><span class="h2">Primary skin disorders</span><span class="headingEndMark"> — </span>Non-malignant dermatoses can resemble SS clinically and pathologically, but cytogenetic/molecular features can be helpful to distinguish them. (See <a class="local">'Pathophysiology'</a> above.)</p><p class="headingAnchor" id="H3376184634"><span class="h3">Psoriasis</span><span class="headingEndMark"> — </span>Although less common since the advent of biologic agents, psoriatic erythroderma still occurs and given the common nature of psoriasis, erythrodermic MF/SS may also occur in patients with psoriasis. </p><p>Clinical clues that may help to distinguish psoriasis from SS/MF include:</p><p class="bulletIndent1"><span class="glyph">●</span>Nails may show the typical pitting or oil spots (not seen in MF/SS)</p><p class="bulletIndent1"><span class="glyph">●</span>Relative sparing of the face</p><p class="bulletIndent1"><span class="glyph">●</span>Scattered pustules and distribution of plaques over joints or in areas of trauma</p><p></p><p>Histologically, psoriasis will typically show psoriasiform epidermal hyperplasia characterized by acanthosis with elongation of the rete ridges and a reactive, primarily perivascular CD4+ lymphocytic dermal infiltrate [<a href="#rid70">70</a>], all of which can be seen in MF/SS. However, typical neutrophil collections in the upper epidermis are not seen in MF/SS, unless there is impetiginization. The absence of both CD7 and CD5 expression on atypical-appearing lymphocytes and presence of folliculotropism are features of MF/SS and not typical of psoriasis. </p><p><em>TCR</em> clonality can be seen with either psoriasis or MF/SS, and it is not diagnostic of MF/SS in the absence of other typical histological findings. Blood of patients with psoriasis will typically not have a significant population of abnormal lymphocytes. (See  <a class="medical medical_review" href="/d/html/5664.html" rel="external">"Psoriasis: Epidemiology, clinical manifestations, and diagnosis", section on 'Erythrodermic psoriasis'</a>.)</p><p class="headingAnchor" id="H3942932229"><span class="h3">Pityriasis rubra pilaris</span><span class="headingEndMark"> — </span>Like erythrodermic MF/SS, pityriasis rubra pilaris (PRP) can demonstrate widespread areas of erythema and scale, including the scalp; however, in PRP there are usually "islands" of sparing [<a href="#rid71">71,72</a>]. </p><p>Follicular hyperkeratosis with a "nutmeg grater"-like texture can mimic follicular MF/SS but is in an atypical distribution (ie, over the dorsum of the hands, knees, and elbows) with PRP. Nails may be thickened and dystrophic as with SS. Keratoderma may occur, but it is often a waxy orange-red color that is distinct from the keratoderma of MF/SS. Pruritus and burning are common symptoms. The histology of PRP typically displays a psoriasiform dermatitis with irregular hyperkeratosis, perivascular lymphohistiocytic infiltrate, alternating vertical and horizontal ortho and parakeratosis, and follicular plugging with shoulder parakeratosis. The biopsy would not be expected to show all the immunophenotypic features of MF, nor would the blood involvement typical of SS be present unless the entire picture is in fact representative of PRP-like MF/SS. (See  <a class="medical medical_review" href="/d/html/15283.html" rel="external">"Pityriasis rubra pilaris: Pathogenesis, clinical manifestations, and diagnosis"</a>.)</p><p class="headingAnchor" id="H3234637299"><span class="h3">Atopic dermatitis</span><span class="headingEndMark"> — </span>Both atopic dermatitis and MF/SS can present with erythroderma. Given the frequency of atopic dermatitis in the general population, it is not uncommon for patients with MF/SS to have both disorders. </p><p>Lichenification, prurigo nodularis, and eyelid involvement are common in long-standing atopic dermatitis, but otherwise, there are no typical skin-associated findings that can help to distinguish atopic dermatitis versus MF/SS short of the presence of concomitant thick plaques, tumors, and/or keratoderma in MF/SS. Both eczema and MF/SS can be accompanied by eosinophilia in the blood and tissue, although it would be unlikely that patients with atopic dermatitis would meet the criteria for B2 staging of MF/SS in the blood. Lymphadenopathy may be seen in MF/SS and in patients with atopy and hyperIgE. On skin biopsy, atopic dermatitis has spongiosis as a primary finding, and this can be a helpful clue. Although spongiosis should not exclude MF/SS from consideration, the algorithm for patch stage MF specifically excludes significant spongiosis for point scoring of pathology [<a href="#rid69">69</a>]. (See <a class="local">'Additional methods to establish diagnosis of SS'</a> above.)</p><p>Finding a CD4+ infiltrate and a clon<em>al TCR</em> rearrangement does not exclude atopic dermatitis as a cause of the erythroderma. (See  <a class="medical medical_review" href="/d/html/1729.html" rel="external">"Atopic dermatitis (eczema): Pathogenesis, clinical manifestations, and diagnosis"</a>.)</p><p>One study suggested that specific immunoglobulin E (IgE) reactivity to common allergens is common in SS [<a href="#rid73">73</a>]. Conversely, another study reported that zero of nine patients with SS had any IgE reactivity to the &gt;103 environmental and food allergens tested in a microarray analysis, but four of nine patients with SS and elevated IgE showed low reactivity to staphylococcal enterotoxins. All four patients with "pre-SS" (erythroderma, elevated total IgE and CD4+ skin infiltrate, but not otherwise meeting criteria for SS) and three of three of the atopic dermatitis controls had both high reactivity towards staphylococcal enterotoxin and multiple environmental and/or food allergens [<a href="#rid74">74</a>]. </p><p class="headingAnchor" id="H369191980"><span class="h2">Skin reactions to various agents</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Contact dermatitis</strong> – Chronic contact dermatitis can mimic erythrodermic MF/SS. This can be a reaction to a topical application (eg, fragrance), exposure to an allergen that is in contact with widespread body areas (eg, fabric softener), systemic exposure to chemicals that are cross reactive with another agent of which the patient has prior contact allergy (eg, ingestion of cashews in someone with allergic reaction to poison ivy), or a generalized photoallergic dermatitis (eg, compositae). </p><p></p><p class="bulletIndent1">Clinically, the distribution of the rash may help to direct one to a particular type of reaction. These patients do not typically have alopecia, nail changes, or keratoderma, such as can be seen with some cases of MF/SS. Histologic changes may be similar to those seen with eczema. Patch testing, which could help reveal the inciting agent, is impossible when the patient is erythrodermic. Systemic steroids may be needed to quiet the rash to a point that patch testing is possible. (See  <a class="medical medical_review" href="/d/html/13655.html" rel="external">"Clinical features and diagnosis of allergic contact dermatitis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Chronic actinic dermatitis</strong> – Chronic actinic dermatitis (formerly called persistent light reaction or actinic reticuloid) can present with erythroderma. To make this diagnosis, three criteria must be fulfilled [<a href="#rid75">75</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Persistent eczematous eruption +/- papules and plaques, predominantly on exposed skin.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Histologic findings compatible with chronic eczema, although changes suggestive of MF may be present.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Reduction in minimal erythema dose to ultraviolet B on normal skin and possibly a change to longer wavelength ultraviolet light as well.</p><p></p><p class="bulletIndent1">Chronic actinic dermatitis may follow photoallergy to topical agents, which then becomes more generalized and persistent. There may be some clinical clues as to the UV light relationship, such as sparing of finger webs, upper eyelids, behind the ears, and inside skin creases. Histologically, this can be very difficult to distinguish from MF and SS, although there is a tendency for the infiltrate to be more CD8+ than CD4+ [<a href="#rid76">76</a>]. In addition, there have been reports of up to 20 percent CD8+ Sézary cells in affected patients [<a href="#rid77">77</a>]. UVB phototesting is mandatory, as is patch and photopatch testing, all of which can be difficult in the face of an erythrodermic reaction. (See  <a class="medical medical_review" href="/d/html/6622.html" rel="external">"Photosensitivity disorders (photodermatoses): Clinical manifestations, diagnosis, and treatment", section on 'Chronic actinic dermatitis'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Scabies</strong> – Diffuse crusted scabies (formerly called "Norwegian" scabies) can mimic erythrodermic MF/SS clinically in its skin presentation, including the presence of dystrophic nails and intense pruritus. Histologic changes can be similar to eczema, except where one is fortunate enough to find signs of the mite, including the mite itself, eggs, or scybala (feces). </p><p></p><p class="bulletIndent1">A scabies prep in multiple areas of the body is usually diagnostic, and a trial of antiscabietic medications can differentiate the two conditions. (See  <a class="medical medical_review" href="/d/html/4038.html" rel="external">"Scabies: Epidemiology, clinical features, and diagnosis", section on 'Diagnosis'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Drug eruption</strong> – Two types of drug eruptions can mimic SS:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>An erythrodermic reaction to a drug that may mimic SS clinically, but on histology typically shows a perivascular lymphohistiocytic infiltrate with eosinophils and a lichenoid vacuolar degeneration that is different from MF/SS.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>An MF/SS mimicker, both clinically and histologically.</p><p></p><p class="bulletIndent1">Drugs should always be considered in the differential diagnosis of MF/SS, and an attempt should be made to stop potentially offending drugs and to avoid substitution with a similar class of drugs for at least two months to see if the rash will improve or resolve without other treatment. In addition, the biologic agents or immunosuppressive agents that are used to treat psoriasis, atopic dermatitis, and a variety of autoimmune disorders can induce a lymphoma, including one that mimics MF/SS. A trial off of the potential offending drug should be performed before initiating directed therapy for the lymphoma. (See  <a class="medical medical_review" href="/d/html/2089.html" rel="external">"Drug eruptions"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Graft-versus-host disease (GVHD)</strong> – GVHD typically occurs in patients who have undergone an allogeneic hematopoietic cell transplantation, where immune competent cells from an allogeneic donor participate in an immune attack on the skin and other host tissues. GVHD rarely occurs after solid organ transplantation or in other settings where an immune-incompetent person receives an infusion of immune competent cells that result in a T cell targeted attack. Acute GVHD may be associated with a widespread erythematous rash or erythroderma. The skin biopsy may reveal dermal lymphocytes with varying degrees of dyskeratosis of epidermal cells. The clinical setting and the associated findings of lung, liver, ocular, and GI disease can usually help distinguish this condition from SS. (See  <a class="medical medical_review" href="/d/html/3549.html" rel="external">"Clinical manifestations, diagnosis, and grading of acute graft-versus-host disease"</a>.)</p><p></p><p class="headingAnchor" id="H1060589"><span class="h2">Other lymphoproliferative or hematologic diseases</span><span class="headingEndMark"> — </span>Erythroderma can be a nonspecific finding of an underlying systemic B or T cell lymphoma. The histologic findings are nonspecific. Imaging should be considered if the etiology is not clear, and if adenopathy is present, a representative lymph node should be biopsied. Any patient with erythroderma without a definitive diagnosis should be followed closely and repeat biopsies performed on skin or new, enlarged lymph nodes. (See  <a class="medical medical_review" href="/d/html/4695.html" rel="external">"Clinical presentation and initial evaluation of non-Hodgkin lymphoma"</a>.)</p><p class="headingAnchor" id="H521128978"><span class="h3">Adult T cell leukemia-lymphoma</span><span class="headingEndMark"> — </span>Adult T cell leukemia-lymphoma (ATLL) can be difficult to distinguish from MF/SS. Both disorders share a similar skin and immunophenotypic picture, although ATLL has a more uniform, strong positivity for CD25. ATLL is much more likely to have disseminated extracutaneous disease with frequent lymphoma in the nodes, liver, bone, and central nervous system. </p><p>A key differentiating feature is the presence of HTLV-I/II in the malignant cells of ATLL, which can be determined by testing for the antibody in the blood. ATLL is common in Japan, the Caribbean, South America, and some areas of the Middle East. (See  <a class="medical medical_review" href="/d/html/4697.html" rel="external">"Clinical manifestations, pathologic features, and diagnosis of adult T cell leukemia-lymphoma"</a>.) </p><p class="headingAnchor" id="H521129025"><span class="h3">T cell prolymphocytic leukemia</span><span class="headingEndMark"> — </span>Both T cell prolymphocytic leukemia (T-PLL) and SS are T cell neoplasms that can involve the blood and skin. The morphology of the "cerebriform" (Sézary cell-like) variant seen in 5 percent of patients with T-PLL resembles the Sézary cells seen in SS. In such cases, SS can be distinguished from T-PLL by the immunophenotype; Sézary cells frequently lack expression for CD2, CD3, CD5, and/or CD7. In contrast, T-PLL cells have strong expression of CD52 and typically express CD2, CD3, and CD7. CD52 is also usually present on malignant T cells in SS and is the target for <a class="drug drug_general" data-topicid="8725" href="/d/drug information/8725.html" rel="external">alemtuzumab</a>. (See  <a class="medical medical_review" href="/d/html/4745.html" rel="external">"Clinical manifestations, pathologic features, and diagnosis of T cell prolymphocytic leukemia"</a>.)</p><p class="headingAnchor" id="H1060612"><span class="h3">Hypereosinophilic syndrome</span><span class="headingEndMark"> — </span>Erythroderma can be seen in patients with the idiopathic hypereosinophilic syndrome, some of whom have a clonal proliferation of T cells with increased production of Th2 cytokines, which may evolve into lymphoma [<a href="#rid78">78-80</a>]. Absence of CD4+CD26- subset and eosinophils &gt;1500/microL in the blood of patients with lymphocytic-variant of hypereosinophilic syndrome (L-HES) is an important distinction between SS and L-HES [<a href="#rid81">81</a>]. (See  <a class="medical medical_review" href="/d/html/2211.html" rel="external">"Hypereosinophilic syndromes: Clinical manifestations, pathophysiology, and diagnosis"</a>.)</p><p class="headingAnchor" id="H615028654"><span class="h2">Idiopathic</span><span class="headingEndMark"> — </span>A large percentage of erythrodermas may defy an exact diagnosis [<a href="#rid82">82-85</a>]. Many of these patients later turn out to have MF or SS, although at presentation they do not meet diagnostic criteria.</p><p class="headingAnchor" id="H20591927"><span class="h1">PROGNOSIS</span><span class="headingEndMark"> — </span>Skin classification, stage of disease, elevated lactate dehydrogenase (LDH), advanced age and comorbidities, race, male sex, peripheral eosinophilia, large cell transformation, and folliculotropic MF have each been associated with poor prognosis and have been variably compiled into validated prognostic indices including the CTCL Severity Index (CTCL-SI), the Cutaneous Lymphoma International Prognostic Index (CLIPi), and the CLIC Prognostic Index [<a href="#rid86">86</a>]. (See  <a class="medical medical_review" href="/d/html/83281.html" rel="external">"Staging and prognosis of mycosis fungoides and Sézary syndrome", section on 'Disease stage'</a>.)</p><p class="headingAnchor" id="H2335410653"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/122000.html" rel="external">"Society guideline links: Primary cutaneous lymphoma"</a>.)</p><p class="headingAnchor" id="H449464055"><span class="h1">SUMMARY</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Description</strong> – Sézary syndrome (SS) and mycosis fungoides (MF) share pathologic findings, clinical features, and staging. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>SS presents de novo with erythroderma and a leukemic phase (circulating malignant T lymphocytes [Sézary cells]).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>A separate designation is given to those patients with MF that evolve into erythroderma with significant blood involvement (eMF).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pathogenesis</strong> – SS is thought to be derived from mature epidermotropic skin-homing CD4+ T cells or central memory T cells. Abnormalities of cell signaling, DNA repair, epigenetic regulators, apoptosis, and cell migration are prominent, but it is uncertain which are malignant drivers and/or secondary processes. Gene expression patterns may distinguish SS from MF. (See <a class="local">'Pathophysiology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical presentation</strong> – Patients with SS commonly present with erythroderma  (<a class="graphic graphic_picture graphicRef83372" href="/d/graphic/83372.html" rel="external">picture 1</a>) with or without lymphadenopathy and pruritus. Other common clinical findings are alopecia, keratoderma, and less commonly involvement of other organs. (See <a class="local">'Clinical manifestations'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Evaluation</strong> – SS should be suspected in a patient presenting with erythroderma or any patient with a persistent erythematous skin eruption and pruritus unresponsive to topical steroids. </p><p></p><p class="bulletIndent1">The evaluation should include a biopsy(s) of involved skin; physical examination; imaging to evaluate potential extracutaneous disease and biopsy of suspected involvement; examination of blood with flow cytometry for an aberrant lymphocyte population; and analysis of T cell receptor<em> (TCR</em>) gene rearrangement in skin, blood, or other biopsy specimen to look for confluence of clonality. (See <a class="local">'Evaluation'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnosis</strong> </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Diagnostic criteria</strong> – SS is a clinicopathologic diagnosis that requires all of the following three criteria: </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Skin</strong> – One of the following:</p><p></p><p class="bulletIndent2">Biopsy is diagnostic of MF/SS </p><p></p><p class="bulletIndent2">or</p><p></p><p class="bulletIndent2">Skin biopsy is compatible/suggestive of MF/SS<strong> plus</strong>:</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Biopsy of enlarged lymph node confirming MF/SS </p><p></p><p class="bulletIndent3">or</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Significant aberrant lymphocyte population in blood with a <em>TCR</em> clone matching that in skin</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Erythroderma</strong> – Erythema covering ≥80 percent of body surface area.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Leukemic blood tumor burden </strong>– Both of the following:</p><p></p><p class="bulletIndent2">Abnormal lymphocytes in the blood sufficient to assign B2 classification, documented by at least one of the following:</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Increased CD4+ cells with an absolute count of &gt;1000 cells/microL of CD4+CD26- or CD4+CD7- phenotype, by flow cytometry.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Sézary cell count ≥1000 cells/microL.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>In the face of lymphopenia (&lt;1000 lymphocytes/microL), increased CD4+CD7- cells ≥40 percent or CD4+CD26- cells ≥30 percent, by flow cytometry.</p><p></p><p class="bulletIndent2">A clonal<em> TCR</em> rearrangement in the blood that matches that in skin.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Additional diagnostic methods</strong> – Biopsies of patch lesions, like erythroderma, may not meet the diagnostic criteria for MF. When the skin biopsy does not provide a firm diagnosis, alternative methods may be used to aid the diagnosis of SS/MF, including a diagnostic pathologic algorithm, evaluation of other involved tissues, and/or adjunctive studies. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Staging</strong> – Staging is discussed separately. (See  <a class="medical medical_review" href="/d/html/83281.html" rel="external">"Staging and prognosis of mycosis fungoides and Sézary syndrome"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Differential diagnosis</strong> – The differential diagnosis includes erythrodermic MF, other primary cutaneous disorders that present with erythroderma, skin reactions to various agents, and other lymphoproliferative or hematologic malignancies that have circulating malignant T cells. (See <a class="local">'Differential diagnosis'</a> above.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Willemze R, Jaffe ES, Burg G, et al. WHO-EORTC classification for cutaneous lymphomas. Blood 2005; 105:3768.</a></li><li><a class="nounderline abstract_t">Olsen E, Vonderheid E, Pimpinelli N, et al. Revisions to the staging and classification of mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC). Blood 2007; 110:1713.</a></li><li><a class="nounderline abstract_t">Olsen EA, Rook AH, Zic J, et al. Sézary syndrome: immunopathogenesis, literature review of therapeutic options, and recommendations for therapy by the United States Cutaneous Lymphoma Consortium (USCLC). J Am Acad Dermatol 2011; 64:352.</a></li><li class="breakAll">World Health Organization classification of tumours of haematopoietic and lymphoid tissues, Swerdlow SH, Campo E, Harris NL, et al. (Eds), IARC Press, Lyon 2008.</li><li><a class="nounderline abstract_t">Campbell JJ, Clark RA, Watanabe R, Kupper TS. Sezary syndrome and mycosis fungoides arise from distinct T-cell subsets: a biologic rationale for their distinct clinical behaviors. Blood 2010; 116:767.</a></li><li><a class="nounderline abstract_t">Kim EJ, Hess S, Richardson SK, et al. Immunopathogenesis and therapy of cutaneous T cell lymphoma. J Clin Invest 2005; 115:798.</a></li><li><a class="nounderline abstract_t">Vowels BR, Cassin M, Vonderheid EC, Rook AH. Aberrant cytokine production by Sezary syndrome patients: cytokine secretion pattern resembles murine Th2 cells. J Invest Dermatol 1992; 99:90.</a></li><li><a class="nounderline abstract_t">Guenova E, Watanabe R, Teague JE, et al. TH2 cytokines from malignant cells suppress TH1 responses and enforce a global TH2 bias in leukemic cutaneous T-cell lymphoma. Clin Cancer Res 2013; 19:3755.</a></li><li><a class="nounderline abstract_t">Clark RA. Regulation gone wrong: a subset of Sézary patients have malignant regulatory T cells. J Invest Dermatol 2009; 129:2747.</a></li><li><a class="nounderline abstract_t">Gibson HM, Mishra A, Chan DV, et al. Impaired proteasome function activates GATA3 in T cells and upregulates CTLA-4: relevance for Sézary syndrome. J Invest Dermatol 2013; 133:249.</a></li><li><a class="nounderline abstract_t">Singer EM, Shin DB, Nattkemper LA, et al. IL-31 is produced by the malignant T-cell population in cutaneous T-Cell lymphoma and correlates with CTCL pruritus. J Invest Dermatol 2013; 133:2783.</a></li><li><a class="nounderline abstract_t">Khodadoust MS, Rook AH, Porcu P, et al. Pembrolizumab in Relapsed and Refractory Mycosis Fungoides and Sézary Syndrome: A Multicenter Phase II Study. J Clin Oncol 2020; 38:20.</a></li><li><a class="nounderline abstract_t">Jariwala N, Benoit B, Kossenkov AV, et al. TIGIT and Helios Are Highly Expressed on CD4+ T Cells in Sézary Syndrome Patients. J Invest Dermatol 2017; 137:257.</a></li><li><a class="nounderline abstract_t">Contassot E, French LE. Targeting apoptosis defects in cutaneous T-cell lymphoma. J Invest Dermatol 2009; 129:1059.</a></li><li><a class="nounderline abstract_t">Wu J, Wood GS. Reduction of Fas/CD95 promoter methylation, upregulation of Fas protein, and enhancement of sensitivity to apoptosis in cutaneous T-cell lymphoma. Arch Dermatol 2011; 147:443.</a></li><li><a class="nounderline abstract_t">García-Díaz N, Piris MÁ, Ortiz-Romero PL, Vaqué JP. Mycosis Fungoides and Sézary Syndrome: An Integrative Review of the Pathophysiology, Molecular Drivers, and Targeted Therapy. Cancers (Basel) 2021; 13.</a></li><li><a class="nounderline abstract_t">van Doorn R, Slieker RC, Boonk SE, et al. Epigenomic Analysis of Sézary Syndrome Defines Patterns of Aberrant DNA Methylation and Identifies Diagnostic Markers. J Invest Dermatol 2016; 136:1876.</a></li><li><a class="nounderline abstract_t">Foss FM, Girardi M. Mycosis Fungoides and Sezary Syndrome. Hematol Oncol Clin North Am 2017; 31:297.</a></li><li><a class="nounderline abstract_t">Choi J, Goh G, Walradt T, et al. Genomic landscape of cutaneous T cell lymphoma. Nat Genet 2015; 47:1011.</a></li><li><a class="nounderline abstract_t">Kiel MJ, Sahasrabuddhe AA, Rolland DCM, et al. Genomic analyses reveal recurrent mutations in epigenetic modifiers and the JAK-STAT pathway in Sézary syndrome. Nat Commun 2015; 6:8470.</a></li><li><a class="nounderline abstract_t">Quaglino P, Fava P, Pileri A, et al. Phenotypical Markers, Molecular Mutations, and Immune Microenvironment as Targets for New Treatments in Patients with Mycosis Fungoides and/or Sézary Syndrome. J Invest Dermatol 2021; 141:484.</a></li><li><a class="nounderline abstract_t">Nebozhyn M, Loboda A, Kari L, et al. Quantitative PCR on 5 genes reliably identifies CTCL patients with 5% to 99% circulating tumor cells with 90% accuracy. Blood 2006; 107:3189.</a></li><li><a class="nounderline abstract_t">Wang L, Ni X, Covington KR, et al. Genomic profiling of Sézary syndrome identifies alterations of key T cell signaling and differentiation genes. Nat Genet 2015; 47:1426.</a></li><li><a class="nounderline abstract_t">McGirt LY, Jia P, Baerenwald DA, et al. Whole-genome sequencing reveals oncogenic mutations in mycosis fungoides. Blood 2015; 126:508.</a></li><li><a class="nounderline abstract_t">Prasad A, Rabionet R, Espinet B, et al. Identification of Gene Mutations and Fusion Genes in Patients with Sézary Syndrome. J Invest Dermatol 2016; 136:1490.</a></li><li><a class="nounderline abstract_t">Ballabio E, Mitchell T, van Kester MS, et al. MicroRNA expression in Sezary syndrome: identification, function, and diagnostic potential. Blood 2010; 116:1105.</a></li><li><a class="nounderline abstract_t">Laharanne E, Oumouhou N, Bonnet F, et al. Genome-wide analysis of cutaneous T-cell lymphomas identifies three clinically relevant classes. J Invest Dermatol 2010; 130:1707.</a></li><li><a class="nounderline abstract_t">Lee CS, Ungewickell A, Bhaduri A, et al. Transcriptome sequencing in Sezary syndrome identifies Sezary cell and mycosis fungoides-associated lncRNAs and novel transcripts. Blood 2012; 120:3288.</a></li><li><a class="nounderline abstract_t">Karenko L, Kähkönen M, Hyytinen ER, et al. Notable losses at specific regions of chromosomes 10q and 13q in the Sézary syndrome detected by comparative genomic hybridization. J Invest Dermatol 1999; 112:392.</a></li><li><a class="nounderline abstract_t">Mao X, Lillington D, Scarisbrick JJ, et al. Molecular cytogenetic analysis of cutaneous T-cell lymphomas: identification of common genetic alterations in Sézary syndrome and mycosis fungoides. Br J Dermatol 2002; 147:464.</a></li><li><a class="nounderline abstract_t">Fischer TC, Gellrich S, Muche JM, et al. Genomic aberrations and survival in cutaneous T cell lymphomas. J Invest Dermatol 2004; 122:579.</a></li><li><a class="nounderline abstract_t">van Doorn R, van Kester MS, Dijkman R, et al. Oncogenomic analysis of mycosis fungoides reveals major differences with Sezary syndrome. Blood 2009; 113:127.</a></li><li><a class="nounderline abstract_t">Pawlaczyk M, Filas V, Sobieska M, et al. No evidence of HTLV-I infection in patients with mycosis fungoides and Sezary syndrome. Neoplasma 2005; 52:52.</a></li><li><a class="nounderline abstract_t">Bazarbachi A, Soriano V, Pawson R, et al. Mycosis fungoides and Sezary syndrome are not associated with HTLV-I infection: an international study. Br J Haematol 1997; 98:927.</a></li><li><a class="nounderline abstract_t">Fouchard N, Mahe A, Huerre M, et al. Cutaneous T cell lymphomas: mycosis fungoides, Sezary syndrome and HTLV-I-associated adult T cell leukemia (ATL) in Mali, West Africa: a clinical, pathological and immunovirological study of 14 cases and a review of the African ATL cases. Leukemia 1998; 12:578.</a></li><li><a class="nounderline abstract_t">Bradford PT, Devesa SS, Anderson WF, Toro JR. Cutaneous lymphoma incidence patterns in the United States: a population-based study of 3884 cases. Blood 2009; 113:5064.</a></li><li><a class="nounderline abstract_t">Saunes M, Nilsen TI, Johannesen TB. Incidence of primary cutaneous T-cell lymphoma in Norway. Br J Dermatol 2009; 160:376.</a></li><li><a class="nounderline abstract_t">Criscione VD, Weinstock MA. Incidence of cutaneous T-cell lymphoma in the United States, 1973-2002. Arch Dermatol 2007; 143:854.</a></li><li><a class="nounderline abstract_t">Desai M, Liu S, Parker S. Clinical characteristics, prognostic factors, and survival of 393 patients with mycosis fungoides and Sézary syndrome in the southeastern United States: a single-institution cohort. J Am Acad Dermatol 2015; 72:276.</a></li><li><a class="nounderline abstract_t">Fischmann AB, Bunn PA Jr, Guccion JG, et al. Exposure to chemicals, physical agents, and biologic agents in mycosis fungoides and the Sézary syndrome. Cancer Treat Rep 1979; 63:591.</a></li><li><a class="nounderline abstract_t">Ghazawi FM, Netchiporouk E, Rahme E, et al. Comprehensive analysis of cutaneous T-cell lymphoma (CTCL) incidence and mortality in Canada reveals changing trends and geographic clustering for this malignancy. Cancer 2017; 123:3550.</a></li><li><a class="nounderline abstract_t">Demierre MF, Gan S, Jones J, Miller DR. Significant impact of cutaneous T-cell lymphoma on patients' quality of life: results of a 2005 National Cutaneous Lymphoma Foundation Survey. Cancer 2006; 107:2504.</a></li><li><a class="nounderline abstract_t">Olsen EA, Whittaker S, Willemze R, et al. Primary cutaneous lymphoma: recommendations for clinical trial design and staging update from the ISCL, USCLC, and EORTC. Blood 2022; 140:419.</a></li><li><a class="nounderline abstract_t">Vij A, Duvic M. Prevalence and severity of pruritus in cutaneous T cell lymphoma. Int J Dermatol 2012; 51:930.</a></li><li><a class="nounderline abstract_t">Saleem MD, Oussedik E, D'Amber V, Feldman SR. Interleukin-31 pathway and its role in atopic dermatitis: a systematic review. J Dermatolog Treat 2017; 28:591.</a></li><li><a class="nounderline abstract_t">Cheson BD, Fisher RI, Barrington SF, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol 2014; 32:3059.</a></li><li><a class="nounderline abstract_t">Bunn PA Jr, Huberman MS, Whang-Peng J, et al. Prospective staging evaluation of patients with cutaneous T-cell lymphomas. Demonstration of a high frequency of extracutaneous dissemination. Ann Intern Med 1980; 93:223.</a></li><li><a class="nounderline abstract_t">Axelrod PI, Lorber B, Vonderheid EC. Infections complicating mycosis fungoides and Sézary syndrome. JAMA 1992; 267:1354.</a></li><li><a class="nounderline abstract_t">Talpur R, Bassett R, Duvic M. Prevalence and treatment of Staphylococcus aureus colonization in patients with mycosis fungoides and Sézary syndrome. Br J Dermatol 2008; 159:105.</a></li><li><a class="nounderline abstract_t">Cariti C, Quaglino P, Lupia T, et al. Infections in Sézary syndrome: A retrospective cohort study of 113 patients. J Am Acad Dermatol 2022; 86:943.</a></li><li><a class="nounderline abstract_t">Lee J, Richardson SK, Melhem ER, et al. Progressive multifocal leukoencephalopathy from JC virus in a patient with advanced mycosis fungoides. J Am Acad Dermatol 2007; 57:893.</a></li><li><a class="nounderline abstract_t">Carson KR, Newsome SD, Kim EJ, et al. Progressive multifocal leukoencephalopathy associated with brentuximab vedotin therapy: a report of 5 cases from the Southern Network on Adverse Reactions (SONAR) project. Cancer 2014; 120:2464.</a></li><li><a class="nounderline abstract_t">Huang KP, Weinstock MA, Clarke CA, et al. Second lymphomas and other malignant neoplasms in patients with mycosis fungoides and Sezary syndrome: evidence from population-based and clinical cohorts. Arch Dermatol 2007; 143:45.</a></li><li><a class="nounderline abstract_t">Herro E, Dicaudo DJ, Davis MD, et al. Review of contemporaneous mycosis fungoides and B-cell malignancy at Mayo Clinic. J Am Acad Dermatol 2009; 61:271.</a></li><li><a class="nounderline abstract_t">Olsen EA, Delzell E, Jegasothy BV. Second malignancies in cutaneous T cell lymphoma. J Am Acad Dermatol 1984; 10:197.</a></li><li><a class="nounderline abstract_t">Cook LB, Fuji S, Hermine O, et al. Revised Adult T-Cell Leukemia-Lymphoma International Consensus Meeting Report. J Clin Oncol 2019; 37:677.</a></li><li><a class="nounderline abstract_t">Vonderheid EC. On the diagnosis of erythrodermic cutaneous T-cell lymphoma. J Cutan Pathol 2006; 33 Suppl 1:27.</a></li><li><a class="nounderline abstract_t">Olsen EA, Whittaker S, Kim YH, et al. Clinical end points and response criteria in mycosis fungoides and Sézary syndrome: a consensus statement of the International Society for Cutaneous Lymphomas, the United States Cutaneous Lymphoma Consortium, and the Cutaneous Lymphoma Task Force of the European Organisation for Research and Treatment of Cancer. J Clin Oncol 2011; 29:2598.</a></li><li><a class="nounderline abstract_t">Nagler AR, Samimi S, Schaffer A, et al. Peripheral blood findings in erythrodermic patients: importance for the differential diagnosis of Sézary syndrome. J Am Acad Dermatol 2012; 66:503.</a></li><li><a class="nounderline abstract_t">Horna P, Wang SA, Wolniak KL, et al. Flow cytometric evaluation of peripheral blood for suspected Sézary syndrome or mycosis fungoides: International guidelines for assay characteristics. Cytometry B Clin Cytom 2021; 100:142.</a></li><li><a class="nounderline abstract_t">Najidh S, Tensen CP, van der Sluijs-Gelling AJ, et al. Improved Sézary cell detection and novel insights into immunophenotypic and molecular heterogeneity in Sézary syndrome. Blood 2021; 138:2539.</a></li><li><a class="nounderline abstract_t">Scarisbrick JJ, Prince HM, Vermeer MH, et al. Cutaneous Lymphoma International Consortium Study of Outcome in Advanced Stages of Mycosis Fungoides and Sézary Syndrome: Effect of Specific Prognostic Markers on Survival and Development of a Prognostic Model. J Clin Oncol 2015; 33:3766.</a></li><li><a class="nounderline abstract_t">Guitart J, Magro C. Cutaneous T-cell lymphoid dyscrasia: a unifying term for idiopathic chronic dermatoses with persistent T-cell clones. Arch Dermatol 2007; 143:921.</a></li><li><a class="nounderline abstract_t">Guitart J. Beyond clonal detection: defining the T-cell clone. Arch Dermatol 2005; 141:1159.</a></li><li><a class="nounderline abstract_t">French LE, Lessin SR, Addya K, et al. Identification of clonal T cells in the blood of patients with systemic sclerosis: positive correlation with response to photopheresis. Arch Dermatol 2001; 137:1309.</a></li><li><a class="nounderline abstract_t">Kirsch IR, Watanabe R, O'Malley JT, et al. TCR sequencing facilitates diagnosis and identifies mature T cells as the cell of origin in CTCL. Sci Transl Med 2015; 7:308ra158.</a></li><li><a class="nounderline abstract_t">Haththotuwa R, Zilinskiene L, Oliff J, et al. Biopsy correlation of surface area vs. single-axis measurements on computed tomography scan of lymph nodes in patients with erythrodermic mycosis fungoides and Sézary syndrome. Br J Dermatol 2017; 177:877.</a></li><li><a class="nounderline abstract_t">Hurabielle C, Michel L, Ram-Wolff C, et al. Expression of Sézary Biomarkers in the Blood of Patients with Erythrodermic Mycosis Fungoides. J Invest Dermatol 2016; 136:317.</a></li><li><a class="nounderline abstract_t">Pimpinelli N, Olsen EA, Santucci M, et al. Defining early mycosis fungoides. J Am Acad Dermatol 2005; 53:1053.</a></li><li><a class="nounderline abstract_t">Tomasini C, Aloi F, Solaroli C, Pippione M. Psoriatic erythroderma: a histopathologic study of forty-five patients. Dermatology 1997; 194:102.</a></li><li><a class="nounderline abstract_t">Clayton BD, Jorizzo JL, Hitchcock MG, et al. Adult pityriasis rubra pilaris: a 10-year case series. J Am Acad Dermatol 1997; 36:959.</a></li><li><a class="nounderline abstract_t">Albert MR, Mackool BT. Pityriasis rubra pilaris. Int J Dermatol 1999; 38:1.</a></li><li><a class="nounderline abstract_t">Scala E, Abeni D, Palazzo P, et al. Specific IgE toward allergenic molecules is a new prognostic marker in patients with Sézary syndrome. Int Arch Allergy Immunol 2012; 157:159.</a></li><li><a class="nounderline abstract_t">Väkevä L, Mäkinen-Kiljunen S, Ranki A. Allergen-specific IgE responses are found in pre-Sézary syndrome patients and in erythrodermic atopic patients but not in true Sézary syndrome patients. J Am Acad Dermatol 2015; 72:352.</a></li><li><a class="nounderline abstract_t">Hawk JL, Magnus IA. Chronic actinic dermatitis--an idiopathic photosensitivity syndrome including actinic reticuloid and photosensitive eczema [proceedings]. Br J Dermatol 1979; 101 Suppl 17:24.</a></li><li><a class="nounderline abstract_t">Leenutaphong V, von Kries R, Hölzle E, Plewig G. Solar urticaria induced by visible light and inhibited by UVA. Photodermatol 1988; 5:170.</a></li><li><a class="nounderline abstract_t">Chu AC, Robinson D, Hawk JL, et al. Immunologic differentiation of the Sézary syndrome due to cutaneous T-cell lymphoma and chronic actinic dermatitis. J Invest Dermatol 1986; 86:134.</a></li><li><a class="nounderline abstract_t">Gotlib J, Cools J, Malone JM 3rd, et al. The FIP1L1-PDGFRalpha fusion tyrosine kinase in hypereosinophilic syndrome and chronic eosinophilic leukemia: implications for diagnosis, classification, and management. Blood 2004; 103:2879.</a></li><li><a class="nounderline abstract_t">Simon HU, Plötz SG, Dummer R, Blaser K. Abnormal clones of T cells producing interleukin-5 in idiopathic eosinophilia. N Engl J Med 1999; 341:1112.</a></li><li><a class="nounderline abstract_t">Roufosse F, Cogan E, Goldman M. Recent advances in pathogenesis and management of hypereosinophilic syndromes. Allergy 2004; 59:673.</a></li><li><a class="nounderline abstract_t">Moerman-Herzog A, Mehdi SJ, Wong HK. Gene Expression Comparison between Sézary Syndrome and Lymphocytic-Variant Hypereosinophilic Syndrome Refines Biomarkers for Sézary Syndrome. Cells 2020; 9.</a></li><li><a class="nounderline abstract_t">Zip C, Murray S, Walsh NM. The specificity of histopathology in erythroderma. J Cutan Pathol 1993; 20:393.</a></li><li><a class="nounderline abstract_t">Sigurdsson V, Toonstra J, van Vloten WA. Idiopathic erythroderma: a follow-up study of 28 patients. Dermatology 1997; 194:98.</a></li><li><a class="nounderline abstract_t">Rothe MJ, Bernstein ML, Grant-Kels JM. Life-threatening erythroderma: diagnosing and treating the "red man". Clin Dermatol 2005; 23:206.</a></li><li><a class="nounderline abstract_t">Botella-Estrada R, Sanmartín O, Oliver V, et al. Erythroderma. A clinicopathological study of 56 cases. Arch Dermatol 1994; 130:1503.</a></li><li><a class="nounderline abstract_t">Berg S, Villasenor-Park J, Haun P, Kim EJ. Multidisciplinary Management of Mycosis Fungoides/Sézary Syndrome. Curr Hematol Malig Rep 2017; 12:234.</a></li></ol></div><div id="topicVersionRevision">Topic 16193 Version 24.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15692063" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : WHO-EORTC classification for cutaneous lymphomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17540844" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Revisions to the staging and classification of mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21145619" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Sézary syndrome: immunopathogenesis, literature review of therapeutic options, and recommendations for therapy by the United States Cutaneous Lymphoma Consortium (USCLC).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21145619" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Sézary syndrome: immunopathogenesis, literature review of therapeutic options, and recommendations for therapy by the United States Cutaneous Lymphoma Consortium (USCLC).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20484084" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Sezary syndrome and mycosis fungoides arise from distinct T-cell subsets: a biologic rationale for their distinct clinical behaviors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15841167" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Immunopathogenesis and therapy of cutaneous T cell lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1607682" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Aberrant cytokine production by Sezary syndrome patients: cytokine secretion pattern resembles murine Th2 cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23785046" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : TH2 cytokines from malignant cells suppress TH1 responses and enforce a global TH2 bias in leukemic cutaneous T-cell lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19901946" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Regulation gone wrong: a subset of Sézary patients have malignant regulatory T cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22951729" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Impaired proteasome function activates GATA3 in T cells and upregulates CTLA-4: relevance for Sézary syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23698099" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : IL-31 is produced by the malignant T-cell population in cutaneous T-Cell lymphoma and correlates with CTCL pruritus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31532724" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Pembrolizumab in Relapsed and Refractory Mycosis Fungoides and Sézary Syndrome: A Multicenter Phase II Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27592800" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : TIGIT and Helios Are Highly Expressed on CD4+ T Cells in Sézary Syndrome Patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19369931" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Targeting apoptosis defects in cutaneous T-cell lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21173302" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Reduction of Fas/CD95 promoter methylation, upregulation of Fas protein, and enhancement of sensitivity to apoptosis in cutaneous T-cell lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33923722" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Mycosis Fungoides and Sézary Syndrome: An Integrative Review of the Pathophysiology, Molecular Drivers, and Targeted Therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27113428" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Epigenomic Analysis of Sézary Syndrome Defines Patterns of Aberrant DNA Methylation and Identifies Diagnostic Markers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28340880" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Mycosis Fungoides and Sezary Syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26192916" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Genomic landscape of cutaneous T cell lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26415585" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Genomic analyses reveal recurrent mutations in epigenetic modifiers and the JAK-STAT pathway in Sézary syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33162051" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Phenotypical Markers, Molecular Mutations, and Immune Microenvironment as Targets for New Treatments in Patients with Mycosis Fungoides and/or Sézary Syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16403914" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Quantitative PCR on 5 genes reliably identifies CTCL patients with 5% to 99% circulating tumor cells with 90% accuracy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26551670" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Genomic profiling of Sézary syndrome identifies alterations of key T cell signaling and differentiation genes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26082451" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Whole-genome sequencing reveals oncogenic mutations in mycosis fungoides.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27039262" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Identification of Gene Mutations and Fusion Genes in Patients with Sézary Syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20448109" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : MicroRNA expression in Sezary syndrome: identification, function, and diagnostic potential.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20130593" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Genome-wide analysis of cutaneous T-cell lymphomas identifies three clinically relevant classes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22936659" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Transcriptome sequencing in Sezary syndrome identifies Sezary cell and mycosis fungoides-associated lncRNAs and novel transcripts.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10084322" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Notable losses at specific regions of chromosomes 10q and 13q in the Sézary syndrome detected by comparative genomic hybridization.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12207585" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Molecular cytogenetic analysis of cutaneous T-cell lymphomas: identification of common genetic alterations in Sézary syndrome and mycosis fungoides.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15086538" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Genomic aberrations and survival in cutaneous T cell lymphomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18832135" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Oncogenomic analysis of mycosis fungoides reveals major differences with Sezary syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15739027" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : No evidence of HTLV-I infection in patients with mycosis fungoides and Sezary syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9326191" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Mycosis fungoides and Sezary syndrome are not associated with HTLV-I infection: an international study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9557617" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Cutaneous T cell lymphomas: mycosis fungoides, Sezary syndrome and HTLV-I-associated adult T cell leukemia (ATL) in Mali, West Africa: a clinical, pathological and immunovirological study of 14 cases and a review of the African ATL cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19279331" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Cutaneous lymphoma incidence patterns in the United States: a population-based study of 3884 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18808419" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Incidence of primary cutaneous T-cell lymphoma in Norway.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17638728" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Incidence of cutaneous T-cell lymphoma in the United States, 1973-2002.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25458019" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Clinical characteristics, prognostic factors, and survival of 393 patients with mycosis fungoides and Sézary syndrome in the southeastern United States: a single-institution cohort.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/445514" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Exposure to chemicals, physical agents, and biologic agents in mycosis fungoides and the Sézary syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28493286" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Comprehensive analysis of cutaneous T-cell lymphoma (CTCL) incidence and mortality in Canada reveals changing trends and geographic clustering for this malignancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17048251" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Significant impact of cutaneous T-cell lymphoma on patients' quality of life: results of a 2005 National Cutaneous Lymphoma Foundation Survey.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34758074" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Primary cutaneous lymphoma: recommendations for clinical trial design and staging update from the ISCL, USCLC, and EORTC.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22788808" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Prevalence and severity of pruritus in cutaneous T cell lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28145790" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Interleukin-31 pathway and its role in atopic dermatitis: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25113753" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6967710" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Prospective staging evaluation of patients with cutaneous T-cell lymphomas. Demonstration of a high frequency of extracutaneous dissemination.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1740857" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Infections complicating mycosis fungoides and Sézary syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18489588" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Prevalence and treatment of Staphylococcus aureus colonization in patients with mycosis fungoides and Sézary syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33975758" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Infections in Sézary syndrome: A retrospective cohort study of 113 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17761357" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Progressive multifocal leukoencephalopathy from JC virus in a patient with advanced mycosis fungoides.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24771533" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Progressive multifocal leukoencephalopathy associated with brentuximab vedotin therapy: a report of 5 cases from the Southern Network on Adverse Reactions (SONAR) project.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17224541" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Second lymphomas and other malignant neoplasms in patients with mycosis fungoides and Sezary syndrome: evidence from population-based and clinical cohorts.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19481294" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Review of contemporaneous mycosis fungoides and B-cell malignancy at Mayo Clinic.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6609176" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Second malignancies in cutaneous T cell lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30657736" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Revised Adult T-Cell Leukemia-Lymphoma International Consensus Meeting Report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16412210" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : On the diagnosis of erythrodermic cutaneous T-cell lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21576639" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Clinical end points and response criteria in mycosis fungoides and Sézary syndrome: a consensus statement of the International Society for Cutaneous Lymphomas, the United States Cutaneous Lymphoma Consortium, and the Cutaneous Lymphoma Task Force of the European Organisation for Research and Treatment of Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22005074" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Peripheral blood findings in erythrodermic patients: importance for the differential diagnosis of Sézary syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32319723" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Flow cytometric evaluation of peripheral blood for suspected Sézary syndrome or mycosis fungoides: International guidelines for assay characteristics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34314480" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Improved Sézary cell detection and novel insights into immunophenotypic and molecular heterogeneity in Sézary syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26438120" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Cutaneous Lymphoma International Consortium Study of Outcome in Advanced Stages of Mycosis Fungoides and Sézary Syndrome: Effect of Specific Prognostic Markers on Survival and Development of a Prognostic Model.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17638739" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Cutaneous T-cell lymphoid dyscrasia: a unifying term for idiopathic chronic dermatoses with persistent T-cell clones.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16172316" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Beyond clonal detection: defining the T-cell clone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11594854" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Identification of clonal T cells in the blood of patients with systemic sclerosis: positive correlation with response to photopheresis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26446955" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : TCR sequencing facilitates diagnosis and identifies mature T cells as the cell of origin in CTCL.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28012157" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Biopsy correlation of surface area vs. single-axis measurements on computed tomography scan of lymph nodes in patients with erythrodermic mycosis fungoides and Sézary syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26763453" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Expression of Sézary Biomarkers in the Blood of Patients with Erythrodermic Mycosis Fungoides.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16310068" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Defining early mycosis fungoides.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9094455" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Psoriatic erythroderma: a histopathologic study of forty-five patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9204063" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Adult pityriasis rubra pilaris: a 10-year case series.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10065602" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Pityriasis rubra pilaris.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21985996" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Specific IgE toward allergenic molecules is a new prognostic marker in patients with Sézary syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25592343" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Allergen-specific IgE responses are found in pre-Sézary syndrome patients and in erythrodermic atopic patients but not in true Sézary syndrome patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/465324" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Chronic actinic dermatitis--an idiopathic photosensitivity syndrome including actinic reticuloid and photosensitive eczema [proceedings].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2466280" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Solar urticaria induced by visible light and inhibited by UVA.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3528307" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Immunologic differentiation of the Sézary syndrome due to cutaneous T-cell lymphoma and chronic actinic dermatitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15070659" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : The FIP1L1-PDGFRalpha fusion tyrosine kinase in hypereosinophilic syndrome and chronic eosinophilic leukemia: implications for diagnosis, classification, and management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10511609" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Abnormal clones of T cells producing interleukin-5 in idiopathic eosinophilia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15180753" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Recent advances in pathogenesis and management of hypereosinophilic syndromes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32872487" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Gene Expression Comparison between Sézary Syndrome and Lymphocytic-Variant Hypereosinophilic Syndrome Refines Biomarkers for Sézary Syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8300924" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : The specificity of histopathology in erythroderma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9094454" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Idiopathic erythroderma: a follow-up study of 28 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15802214" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Life-threatening erythroderma: diagnosing and treating the "red man".</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7986122" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Erythroderma. A clinicopathological study of 56 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28540671" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Multidisciplinary Management of Mycosis Fungoides/Sézary Syndrome.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
